Global central banks’ willingness to buy gold reaches highest level since 2018, gold price pullbacks seen as allocation opportunities
BlockBeats reported that on June 16, according to the latest survey published by the World Gold Council, global central banks' willingness to allocate gold continues to rise. Against the backdrop of price corrections in a high gold price environment, "buying the dip" is becoming an important strategy for reserve management in some countries.
The survey conducted by the organization in conjunction with YouGov, covering 74 central banks, revealed that 45% of respondents plan to increase gold reserves in the next 12 months. This is the highest level since the statistics began in 2018. Additionally, only one central bank stated it would reduce its gold holdings. This structural result shows that despite the recent pullback from high prices, official entities globally have not weakened their long-term demand for gold allocation.
The report noted that over the past three years, consistent net buying by central banks has doubled gold prices, but since 2026, the market environment has shifted. The situation in the Middle East has pushed energy price volatility and strengthened market expectations for "interest rates staying high for a long time," which has suppressed the short-term appeal of yieldless assets like gold. Coupled with speculative money temporarily exiting, gold prices have fallen to their lowest since November last year.
Structurally, emerging markets and developing economies remain the main drivers of future gold purchases. The survey shows about 53% of central banks in this category plan to further increase gold holdings, while only 18% of central banks in developed economies intend to do so, reflecting significant differences in diversification and risk hedging strategies between economic groups.
Shaokai Fan commented that price corrections are reactivating the buying strength of some central banks: "The price drop has provided some central banks with entry opportunities." He noted that in 2025, many central banks chose to wait and see due to high gold prices, but the current correction is changing these decision-making dynamics.
In terms of gold purchasing methods, about half of the central banks planning to increase gold holdings prefer using their local currency to purchase gold directly from their domestic mining systems, reducing the consumption of foreign exchange reserves. Another 38% choose to rebalance by selling other reserve assets. This indicates that gold is gradually evolving from being a "foreign exchange reserve substitute" to a "tool for asset reallocation within the system."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Caribou shares fall after discontinuing cell therapy program and launching strategic review
On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)
VWO ETF Closes Flat
This article was automatically generated using Dow Jones technology. Shares of Vanguard FTSE Emerging Markets ETF were flat at $60.62 Tuesday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,818.93. This was the fund's third consecutive day of gains. The ETF's shares closed 1.5% below the 52-week high of $61.53 seen on September 4, 2026. Trading volume was 4,661,177, compared to the 65-day average trading volume of 7,016,590. As of October 5, the fund's net asset value totaled $60.76 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:37 ET (20:37 GMT)
Novavax Inc. Stock Slides 9.9%, Underperforms Peers
This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Novavax Inc. shed 9.9% to $11.32 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 27,599.79 and the Dow Jones Industrial Average rising 0.5% to 51,521.28. Novavax Inc. closed 15.4% below its 52-week high of $13.39, which the company achieved on October 5th. The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.7% to $254.78, Pfizer Inc. rose 0.3% to $27.50, and Merck & Co. Inc. rose 1.72% to $141.94. Trading volume totaled 19.3 million, compared to the 50-day average of 5.3 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:33 ET (20:33 GMT)
Evogene announces special shareholder meeting
Evogene will hold a special general meeting of shareholders in Rehovot, Israel on Nov. 10, 2026. Shareholders will vote on electing Oz Adler and Dr. Adi Zuloff-Shani to the board. Ballots will also cover the election of Itay Maroz and Shahar Zadok, subject to approval of a cooperation agreement. The meeting will also vote on a cooperation agreement between Evogene and L.I.A. Pure Capital and Invest-Pro Shukai Hon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004722), on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
